ReviewAnnals of medicine2026
Extracorporeal therapies in the management of paraquat poisoning: a comprehensive review of current evidence.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Severe paraquat poisoning: a 5-year follow-up of a survivor.World journal of emergency medicine · 2026Article
- A retrospective analysis of paraquat and diquat poisoning: a single-center experience.Frontiers in medicine · 2026Article
- Impacts of hemoperfusion combined with continuous renal replacement therapy on renal function and immune function in patients with acute renal failure caused by poisoning.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionParaquat (PQ) poisoning has a high mortality rate due to rapid systemic distribution and oxidative organ damage, particularly in the lungs. Conventional therapies are often inadequate, prompting interest in extracorporeal therapies to enhance PQ clearance.
methodsThis narrative review synthesizes current evidence on hemoperfusion (HP), continuous renal replacement therapy (CRRT), hemodiafiltration (HDF), haemodialysis (HD) and therapeutic plasma exchange (TPE) in PQ poisoning. Studies were evaluated for therapeutic mechanisms, clinical outcomes and optimal implementation strategies.
resultsEarly and repeated HP, especially within 4-6 h post-ingestion, improves survival by directly adsorbing PQ. CRRT supports renal function and facilitates sustained toxin removal, with the best outcomes observed when combined with HP. HDF allows prolonged clearance but has limited supporting data. HD, while useful for managing acute kidney injury, appears ineffective for PQ elimination and may increase mortality. TPE shows potential benefits in severe cases if administered early, but evidence is limited to small studies. Combination therapies (e.g. HP with CRRT or HD) demonstrate synergistic effects in improving survival and organ support.
conclusionsExtracorporeal therapies, particularly early HP and HP combined with CRRT, are promising strategies in PQ poisoning. HD should not be the primary detoxification method but remains important for supportive care. TPE may be beneficial in selected cases. Further randomized trials are needed to optimize treatment protocols and validate combined approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.